DekaBank Deutsche Girozentrale Has $115.62 Million Holdings in Quest Diagnostics Incorporated (NYSE:DGX)

DekaBank Deutsche Girozentrale increased its position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 2.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 748,680 shares of the medical research company's stock after buying an additional 15,047 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.67% of Quest Diagnostics worth $115,621,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. GHP Investment Advisors Inc. boosted its holdings in Quest Diagnostics by 2.7% during the third quarter. GHP Investment Advisors Inc. now owns 36,157 shares of the medical research company's stock valued at $5,613,000 after purchasing an additional 943 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Quest Diagnostics by 14.5% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 10,657 shares of the medical research company's stock valued at $1,655,000 after purchasing an additional 1,346 shares in the last quarter. PFG Investments LLC acquired a new stake in Quest Diagnostics during the third quarter valued at approximately $279,000. Forsta AP Fonden boosted its holdings in Quest Diagnostics by 13.0% during the third quarter. Forsta AP Fonden now owns 28,600 shares of the medical research company's stock valued at $4,440,000 after purchasing an additional 3,300 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Quest Diagnostics by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,345 shares of the medical research company's stock valued at $1,601,000 after purchasing an additional 2,852 shares in the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Karthik Kuppusamy sold 1,990 shares of the business's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total value of $304,987.40. Following the completion of the transaction, the senior vice president now owns 11,459 shares of the company's stock, valued at $1,756,206.34. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.79% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on DGX shares. Citigroup lifted their price objective on Quest Diagnostics from $165.00 to $185.00 and gave the company a "buy" rating in a report on Wednesday. StockNews.com cut shares of Quest Diagnostics from a "buy" rating to a "hold" rating in a research note on Wednesday. Baird R W upgraded shares of Quest Diagnostics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday. Piper Sandler lifted their target price on shares of Quest Diagnostics from $145.00 to $150.00 and gave the company a "neutral" rating in a research note on Monday, July 29th. Finally, Robert W. Baird upgraded shares of Quest Diagnostics from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $157.00 to $182.00 in a research note on Wednesday. Nine analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Quest Diagnostics currently has an average rating of "Hold" and an average target price of $163.33.

Quest Diagnostics Trading Down 1.9 %

Shares of Quest Diagnostics stock traded down $2.95 on Friday, hitting $155.04. 814,738 shares of the company's stock traded hands, compared to its average volume of 925,746. The firm's 50-day moving average price is $153.12 and its two-hundred day moving average price is $144.83. The stock has a market capitalization of $17.22 billion, a PE ratio of 20.87, a price-to-earnings-growth ratio of 2.45 and a beta of 0.89. Quest Diagnostics Incorporated has a one year low of $123.04 and a one year high of $160.95. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.00 and a quick ratio of 0.91.

Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its earnings results on Tuesday, October 22nd. The medical research company reported $2.30 EPS for the quarter, beating the consensus estimate of $2.26 by $0.04. The company had revenue of $2.49 billion during the quarter, compared to analysts' expectations of $2.43 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The business's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.22 EPS. On average, research analysts expect that Quest Diagnostics Incorporated will post 8.89 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, October 21st. Shareholders of record on Friday, October 4th were given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.93%. The ex-dividend date was Friday, October 4th. Quest Diagnostics's payout ratio is 40.38%.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.